Lyophilization USA Conference 2017

SMi Group16 - 17 November 2017, Iselin, USA.
As biopharmaceuticals continue to dominate the market the need for greater shelf life and protein stability has increased. For many biological products lyophilization is a necessity and the technology is constantly advancing. As manufacturing demands increase the global lyophilization market for pharmaceutical and biotechnology products is expected to reach $2.66 billion by 2019 and this a trend that is likely to continue as we push the boundaries of biopharmaceutical formulation and transport.

One of the main challenges in pharmaceutical lyophilization continues to be the scale- up and the implementation of QbD protocols for the optimization of cycles. Several companies are researching and developing ways to facilitate commercial bulk lyophilisation of vaccines, protein and cells while also reducing costs.

Lyophilization USA will gather leading experts from top pharma companies to discuss the latest cutting-edge developments in freeze drying, as well as solutions to on-going industry challenges.

Key Topics Addressed:

  • The impact of controlled nucleation on product quality and the technology being used for controlled ice nucleation.
  • Examining the development and scale up of a freeze-drying cycle for biotherapeutics.
  • Highlighting the approaches to effective holistic packaging and innovative design.

Featured Speakers:

  • Lokesh Kumar, Associated Scientist, Genentech
  • Charlie Tang, Associate Director, Formulation Development, Regeneron Pharmaceuticals
  • Guido Schmitz, Global Head of Packaging & Technology Innovation, Bayer Consumer Care
  • Perceval Sondag, Principal Statistician, Arlenda
  • Eric Munson, Professor, Pharmaceutical Sciences, University of Kentucky
  • Kelly Forney Stevens, Drug Product Development, GSK Vaccines
  • Melissa Lash, Scientist, Large Molecule Drug Development, Johnson & Johnson

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/northamerica/Lyophilisation-USA

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Amgen and Humana partner for improved health outco…

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to i...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]